期刊文献+

高效液相色谱法测定人脑脊液中利奈唑胺浓度 被引量:7

Determination of linezolid concentration in human cerebrospinal fluid by high performance liquid chromatography
原文传递
导出
摘要 目的:建立高效液相色谱法快速测定人脑脊液中利奈唑胺浓度并对危重患者进行药物浓度监测。方法:采用外标法,色谱柱:ZORBAX Edipse XDB-C18(4.6 mm×150 mm,5μm);流动相:乙腈-水(23∶77);流速:1.0mL·min-1;柱温:30℃;紫外检测波长:254 nm,并利用建立的方法对危重患者进行利奈唑胺脑脊液浓度的监测。结果:利奈唑胺在0.31~40 mg.L-1范围内线性关系良好(r=0.999 9),最低定量限为0.31 mg.L-1,平均绝对回收率为46.8%,平均相对回收率为96.99%,高、中、低3个浓度日内、日间精密度的RSD均小于<5%。另外,所监测的危重患者中,利奈唑胺不同时期在脑脊液中的浓度变化很大。结论:所建立的高效液相色谱法简单、快捷、灵敏、准确,可用于监测利奈唑胺在脑脊液中的浓度。 OBJECTIVE To establish a method for determining the concentration of linezolid in human cerebrospinal fluid by HPLC, and to determine linezolid concentration in craniocerebral injury patients. METHODS The external standard method was used, the separation was performed on a ZORBAX Edipse XDB-C18(4. 6 mm×150mm,5μm), the mobile phase consisted of acetonitrile:water (23:77) with a flow rate of 1.0 mL.min-1 ,the UV detection wavelength was 254 nm. RESULTS The calibration curves of linezolid showed good linear regression in the range of 0. 31 - 40 mg.L- 1 (r = 0 . 999 9), the limits of detection was 0. 31 mg. L-1. The mean absolute recovery was 46. 8%, and the relative recovery was 96. 99~. Intra and inter-day variations were all less than 5 0/00. In addition, in craniocerebral injury patients, linezolid concentration in cerebrospinal fluid varied much in the different periods of disease. CONCLUSION The established method is simple, rapid, sensitive and accurate for determining linezolid level in human cerebrospinal fluid.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2012年第10期785-788,共4页 Chinese Journal of Hospital Pharmacy
关键词 利奈唑胺 高效液相色谱仪 脑脊液 治疗药物监测 linezolid high performance liquid chromatography cerebrospinal fluid therapeutic drug monitoring
  • 相关文献

参考文献7

二级参考文献79

共引文献107

同被引文献53

  • 1赵敏,赵国君,张勇.新碳青霉烯类抗生素比阿培南[J].中国临床药理学杂志,2005,21(5):390-392. 被引量:26
  • 2万洪光.结核性脑膜炎早期诊断与治疗中存在问题的分析[J].临床肺科杂志,2007,12(3):290-290. 被引量:28
  • 3马坞,朱莉贞,潘毓莹.结核病[M].北京:人民卫生出版社,2006:285. 被引量:50
  • 4中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007~2008年)[M].北京:人民卫生出版社,2010.5-61. 被引量:5
  • 5CDC. Extrapulmonary tuberculosis eases and percentages by site of disease: reporting areas, 2005 [ M ]. Atlanta: Centers for Disease Control and Prevention ,2005. 被引量:1
  • 6Global tuberculosis control: key findings from the December 2009 WHO report. Wkly Epidemiol Ree,2010,85(9) :69-80. 被引量:1
  • 7Thwaites GE ,Chau Tr,Fan'ar JJ. Improving the bacteriological diagosis of tuberculous meningitis[ J]. J Clin Microbio1,2004,42( l ) :378-379. 被引量:1
  • 8R. Bryan Rack, Michael Olin, Cristina A. Baker, et al. Molitor, and Phillip K. Peterson. Central Nervous System Tuberculosis: Pathogenesis and Clinical Aspects[J]. Clin Microbiol Rev,2008,21 (2) :243-261. 被引量:1
  • 9Katiyar SK, Bihari S, Prakash S, et al. A randomised controlled trial of high-doseisoniazid adjuvant therapy for muhidrug-resistant tuber- culosis [ J ]. Int J Tuberc Lung Dis,2008,12 ( 2 ) : 139-145. 被引量:1
  • 10Shaun E Beming,Teresa A Cherry, Michael D Iseman. Novel Treat- ment of Meningitis Caused by Muhidrug-Resistant Mycobacterium tuberculosis with Intrathecal Levofl oxacin and Amikacin : Case Re- port[J]. Clin Infect Dis,2001,32(4) :643-646. 被引量:1

引证文献7

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部